Cargando…

A new twist on an old idea: a two‐dimensional speckle tracking assessment of cyclosporine as a therapeutic alternative for heart failure with preserved ejection fraction

We recently reported that mitochondrial dysfunction, characterized by increased mitochondrial permeability transition (MPT), was present in a translational swine model of heart failure with preserved ejection fraction (HFpEF). Cyclophilin D is a key component of the MPT pore, therefore, the purpose...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiemstra, Jessica A., Liu, Songtao, Ahlman, Mark A., Schuleri, Karl H., Lardo, Albert C., Baines, Christopher P., Dellsperger, Kevin C., Bluemke, David A., Emter, Craig A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970750/
https://www.ncbi.nlm.nih.gov/pubmed/24744855
http://dx.doi.org/10.1002/phy2.174
_version_ 1782309424478552064
author Hiemstra, Jessica A.
Liu, Songtao
Ahlman, Mark A.
Schuleri, Karl H.
Lardo, Albert C.
Baines, Christopher P.
Dellsperger, Kevin C.
Bluemke, David A.
Emter, Craig A.
author_facet Hiemstra, Jessica A.
Liu, Songtao
Ahlman, Mark A.
Schuleri, Karl H.
Lardo, Albert C.
Baines, Christopher P.
Dellsperger, Kevin C.
Bluemke, David A.
Emter, Craig A.
author_sort Hiemstra, Jessica A.
collection PubMed
description We recently reported that mitochondrial dysfunction, characterized by increased mitochondrial permeability transition (MPT), was present in a translational swine model of heart failure with preserved ejection fraction (HFpEF). Cyclophilin D is a key component of the MPT pore, therefore, the purpose of this study was to test the efficacy of a novel cyclosporine (CsA) dosing scheme as a therapeutic alternative for HFpEF. Computed tomography (CT), two‐dimensional speckle tracking two‐dimensional speckle tracking (2DST), and invasive hemodynamics were used to evaluate cardiac function. CT imaging showed 14 weeks of CsA treatment caused eccentric myocardial remodeling (contrasting concentric remodeling in untreated HF animals) and elevated systemic pressures. 2DST detected left ventricular (LV) mechanics associated with systolic and diastolic dysfunction prior to the onset of significantly increased LV end diastolic pressure including: (1) decreased systolic apical rotation rate, longitudinal displacement, and longitudinal/radial/circumferential strain; (2) decreased early diastolic untwisting and longitudinal strain rate; and (3) increased late diastolic radial/circumferential mitral strain rate. LV mechanics associated with systolic and diastolic impairment was enhanced to a greater extent than seen in untreated HF animals following CsA treatment. In conclusion, CsA treatment accelerated the development of heart failure, including dilatory LV remodeling and impaired systolic and diastolic mechanics. Although our findings do not support CsA as a viable therapy for HFpEF, 2DST was effective in differentiating between progressive gradations of developing HF and detecting diastolic impairment prior to the development of overt diastolic dysfunction.
format Online
Article
Text
id pubmed-3970750
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Wiley Periodicals, Inc.
record_format MEDLINE/PubMed
spelling pubmed-39707502014-03-31 A new twist on an old idea: a two‐dimensional speckle tracking assessment of cyclosporine as a therapeutic alternative for heart failure with preserved ejection fraction Hiemstra, Jessica A. Liu, Songtao Ahlman, Mark A. Schuleri, Karl H. Lardo, Albert C. Baines, Christopher P. Dellsperger, Kevin C. Bluemke, David A. Emter, Craig A. Physiol Rep Original Research We recently reported that mitochondrial dysfunction, characterized by increased mitochondrial permeability transition (MPT), was present in a translational swine model of heart failure with preserved ejection fraction (HFpEF). Cyclophilin D is a key component of the MPT pore, therefore, the purpose of this study was to test the efficacy of a novel cyclosporine (CsA) dosing scheme as a therapeutic alternative for HFpEF. Computed tomography (CT), two‐dimensional speckle tracking two‐dimensional speckle tracking (2DST), and invasive hemodynamics were used to evaluate cardiac function. CT imaging showed 14 weeks of CsA treatment caused eccentric myocardial remodeling (contrasting concentric remodeling in untreated HF animals) and elevated systemic pressures. 2DST detected left ventricular (LV) mechanics associated with systolic and diastolic dysfunction prior to the onset of significantly increased LV end diastolic pressure including: (1) decreased systolic apical rotation rate, longitudinal displacement, and longitudinal/radial/circumferential strain; (2) decreased early diastolic untwisting and longitudinal strain rate; and (3) increased late diastolic radial/circumferential mitral strain rate. LV mechanics associated with systolic and diastolic impairment was enhanced to a greater extent than seen in untreated HF animals following CsA treatment. In conclusion, CsA treatment accelerated the development of heart failure, including dilatory LV remodeling and impaired systolic and diastolic mechanics. Although our findings do not support CsA as a viable therapy for HFpEF, 2DST was effective in differentiating between progressive gradations of developing HF and detecting diastolic impairment prior to the development of overt diastolic dysfunction. Wiley Periodicals, Inc. 2013-12-05 /pmc/articles/PMC3970750/ /pubmed/24744855 http://dx.doi.org/10.1002/phy2.174 Text en © 2013 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of the American Physiological Society and The Physiological Society. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/3.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Hiemstra, Jessica A.
Liu, Songtao
Ahlman, Mark A.
Schuleri, Karl H.
Lardo, Albert C.
Baines, Christopher P.
Dellsperger, Kevin C.
Bluemke, David A.
Emter, Craig A.
A new twist on an old idea: a two‐dimensional speckle tracking assessment of cyclosporine as a therapeutic alternative for heart failure with preserved ejection fraction
title A new twist on an old idea: a two‐dimensional speckle tracking assessment of cyclosporine as a therapeutic alternative for heart failure with preserved ejection fraction
title_full A new twist on an old idea: a two‐dimensional speckle tracking assessment of cyclosporine as a therapeutic alternative for heart failure with preserved ejection fraction
title_fullStr A new twist on an old idea: a two‐dimensional speckle tracking assessment of cyclosporine as a therapeutic alternative for heart failure with preserved ejection fraction
title_full_unstemmed A new twist on an old idea: a two‐dimensional speckle tracking assessment of cyclosporine as a therapeutic alternative for heart failure with preserved ejection fraction
title_short A new twist on an old idea: a two‐dimensional speckle tracking assessment of cyclosporine as a therapeutic alternative for heart failure with preserved ejection fraction
title_sort new twist on an old idea: a two‐dimensional speckle tracking assessment of cyclosporine as a therapeutic alternative for heart failure with preserved ejection fraction
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970750/
https://www.ncbi.nlm.nih.gov/pubmed/24744855
http://dx.doi.org/10.1002/phy2.174
work_keys_str_mv AT hiemstrajessicaa anewtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT liusongtao anewtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT ahlmanmarka anewtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT schulerikarlh anewtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT lardoalbertc anewtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT baineschristopherp anewtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT dellspergerkevinc anewtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT bluemkedavida anewtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT emtercraiga anewtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT hiemstrajessicaa newtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT liusongtao newtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT ahlmanmarka newtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT schulerikarlh newtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT lardoalbertc newtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT baineschristopherp newtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT dellspergerkevinc newtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT bluemkedavida newtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction
AT emtercraiga newtwistonanoldideaatwodimensionalspeckletrackingassessmentofcyclosporineasatherapeuticalternativeforheartfailurewithpreservedejectionfraction